Estimated health benefits, costs and cost-effectiveness of eliminating industrial trans-fatty acids in Nigeria: cost-effectiveness analysis
Introduction Nigeria is committed to reducing industrial trans-fatty acids (iTFA) from the food supply, but the potential health gains, costs and cost-effectiveness are unknown.Methods The effect on ischaemic heart disease (IHD) burden, costs and cost-effectiveness of a mandatory iTFA limit (≤2% of...
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMJ Publishing Group
2024-04-01
|
| Series: | BMJ Global Health |
| Online Access: | https://gh.bmj.com/content/9/4/e014294.full |
| _version_ | 1827171734573285376 |
|---|---|
| author | J Lennert Veerman Mark D Huffman Mary Njeri Wanjau Liping Huang Matti Marklund Jason HY Wu Leopold N Aminde Boni M Ale Adedayo E Ojo Clementina E Okoro Abimbola Adegboye Dike B Ojji |
| author_facet | J Lennert Veerman Mark D Huffman Mary Njeri Wanjau Liping Huang Matti Marklund Jason HY Wu Leopold N Aminde Boni M Ale Adedayo E Ojo Clementina E Okoro Abimbola Adegboye Dike B Ojji |
| author_sort | J Lennert Veerman |
| collection | DOAJ |
| description | Introduction Nigeria is committed to reducing industrial trans-fatty acids (iTFA) from the food supply, but the potential health gains, costs and cost-effectiveness are unknown.Methods The effect on ischaemic heart disease (IHD) burden, costs and cost-effectiveness of a mandatory iTFA limit (≤2% of all fats) for foods in Nigeria were estimated using Markov cohort models. Data on demographics, IHD epidemiology and trans-fatty acid intake were derived from the 2019 Global Burden of Disease Study. Avoided IHD events and deaths; health-adjusted life years (HALYs) gained; and healthcare, policy implementation and net costs were estimated over 10 years and the population’s lifetime. Incremental cost-effectiveness ratios using net costs and HALYs gained (both discounted at 3%) were used to assess cost-effectiveness.Results Over the first 10 years, a mandatory iTFA limit (assumed to eliminate iTFA intake) was estimated to prevent 9996 (95% uncertainty interval: 8870 to 11 118) IHD deaths and 66 569 (58 862 to 74 083) IHD events, and to save US$90 million (78 to 102) in healthcare costs. The corresponding lifetime estimates were 259 934 (228 736 to 290 191), 479 308 (95% UI 420 472 to 538 177) and 518 (450 to 587). Policy implementation costs were estimated at US$17 million (11 to 23) over the first 10 years, and US$26 million USD (19 to 33) over the population’s lifetime. The intervention was estimated to be cost-saving, and findings were robust across several deterministic sensitivity analyses.Conclusion Our findings support mandating a limit of iTFAs as a cost-saving strategy to reduce the IHD burden in Nigeria. |
| first_indexed | 2024-04-24T08:09:54Z |
| format | Article |
| id | doaj.art-e2fe8677a5f84fa7a8ef09003928cfda |
| institution | Directory Open Access Journal |
| issn | 2059-7908 |
| language | English |
| last_indexed | 2025-03-21T03:12:34Z |
| publishDate | 2024-04-01 |
| publisher | BMJ Publishing Group |
| record_format | Article |
| series | BMJ Global Health |
| spelling | doaj.art-e2fe8677a5f84fa7a8ef09003928cfda2024-08-01T22:50:09ZengBMJ Publishing GroupBMJ Global Health2059-79082024-04-019410.1136/bmjgh-2023-014294Estimated health benefits, costs and cost-effectiveness of eliminating industrial trans-fatty acids in Nigeria: cost-effectiveness analysisJ Lennert Veerman0Mark D Huffman1Mary Njeri Wanjau2Liping Huang3Matti Marklund4Jason HY Wu5Leopold N Aminde6Boni M Ale7Adedayo E Ojo8Clementina E Okoro9Abimbola Adegboye10Dike B Ojji11School of Medicine and Dentistry, Griffith University, Gold Coast, Queensland, AustraliaFood Policy, The George Institute for Global Health, Newtown, New South Wales, AustraliaSchool of Medicine and Dentistry, Griffith University, Gold Coast, Queensland, AustraliaDepartment of Neurology, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, ChinaWelch Center for Prevention, Epidemiology, and Clinical Research, Johns Hopkins University, Baltimore, Maryland, USAFood Policy, The George Institute for Global Health, Newtown, New South Wales, AustraliaSchool of Medicine and Dentistry, Griffith University, Gold Coast, Queensland, AustraliaCardiovascular Research Unit, University of Abuja Teaching Hospital, Gwagwalada, Abuja, NigeriaCardiovascular Research Unit, University of Abuja Teaching Hospital, Gwagwalada, Abuja, NigeriaFederal Capital Territory Primary Health Care Board, Abuja, NigeriaNational Agency for Food and Drug Administration and Control, Abuja, Federal Capital Territory, NigeriaCardiovascular Research Unit, University of Abuja Teaching Hospital, Gwagwalada, Abuja, NigeriaIntroduction Nigeria is committed to reducing industrial trans-fatty acids (iTFA) from the food supply, but the potential health gains, costs and cost-effectiveness are unknown.Methods The effect on ischaemic heart disease (IHD) burden, costs and cost-effectiveness of a mandatory iTFA limit (≤2% of all fats) for foods in Nigeria were estimated using Markov cohort models. Data on demographics, IHD epidemiology and trans-fatty acid intake were derived from the 2019 Global Burden of Disease Study. Avoided IHD events and deaths; health-adjusted life years (HALYs) gained; and healthcare, policy implementation and net costs were estimated over 10 years and the population’s lifetime. Incremental cost-effectiveness ratios using net costs and HALYs gained (both discounted at 3%) were used to assess cost-effectiveness.Results Over the first 10 years, a mandatory iTFA limit (assumed to eliminate iTFA intake) was estimated to prevent 9996 (95% uncertainty interval: 8870 to 11 118) IHD deaths and 66 569 (58 862 to 74 083) IHD events, and to save US$90 million (78 to 102) in healthcare costs. The corresponding lifetime estimates were 259 934 (228 736 to 290 191), 479 308 (95% UI 420 472 to 538 177) and 518 (450 to 587). Policy implementation costs were estimated at US$17 million (11 to 23) over the first 10 years, and US$26 million USD (19 to 33) over the population’s lifetime. The intervention was estimated to be cost-saving, and findings were robust across several deterministic sensitivity analyses.Conclusion Our findings support mandating a limit of iTFAs as a cost-saving strategy to reduce the IHD burden in Nigeria.https://gh.bmj.com/content/9/4/e014294.full |
| spellingShingle | J Lennert Veerman Mark D Huffman Mary Njeri Wanjau Liping Huang Matti Marklund Jason HY Wu Leopold N Aminde Boni M Ale Adedayo E Ojo Clementina E Okoro Abimbola Adegboye Dike B Ojji Estimated health benefits, costs and cost-effectiveness of eliminating industrial trans-fatty acids in Nigeria: cost-effectiveness analysis BMJ Global Health |
| title | Estimated health benefits, costs and cost-effectiveness of eliminating industrial trans-fatty acids in Nigeria: cost-effectiveness analysis |
| title_full | Estimated health benefits, costs and cost-effectiveness of eliminating industrial trans-fatty acids in Nigeria: cost-effectiveness analysis |
| title_fullStr | Estimated health benefits, costs and cost-effectiveness of eliminating industrial trans-fatty acids in Nigeria: cost-effectiveness analysis |
| title_full_unstemmed | Estimated health benefits, costs and cost-effectiveness of eliminating industrial trans-fatty acids in Nigeria: cost-effectiveness analysis |
| title_short | Estimated health benefits, costs and cost-effectiveness of eliminating industrial trans-fatty acids in Nigeria: cost-effectiveness analysis |
| title_sort | estimated health benefits costs and cost effectiveness of eliminating industrial trans fatty acids in nigeria cost effectiveness analysis |
| url | https://gh.bmj.com/content/9/4/e014294.full |
| work_keys_str_mv | AT jlennertveerman estimatedhealthbenefitscostsandcosteffectivenessofeliminatingindustrialtransfattyacidsinnigeriacosteffectivenessanalysis AT markdhuffman estimatedhealthbenefitscostsandcosteffectivenessofeliminatingindustrialtransfattyacidsinnigeriacosteffectivenessanalysis AT marynjeriwanjau estimatedhealthbenefitscostsandcosteffectivenessofeliminatingindustrialtransfattyacidsinnigeriacosteffectivenessanalysis AT lipinghuang estimatedhealthbenefitscostsandcosteffectivenessofeliminatingindustrialtransfattyacidsinnigeriacosteffectivenessanalysis AT mattimarklund estimatedhealthbenefitscostsandcosteffectivenessofeliminatingindustrialtransfattyacidsinnigeriacosteffectivenessanalysis AT jasonhywu estimatedhealthbenefitscostsandcosteffectivenessofeliminatingindustrialtransfattyacidsinnigeriacosteffectivenessanalysis AT leopoldnaminde estimatedhealthbenefitscostsandcosteffectivenessofeliminatingindustrialtransfattyacidsinnigeriacosteffectivenessanalysis AT bonimale estimatedhealthbenefitscostsandcosteffectivenessofeliminatingindustrialtransfattyacidsinnigeriacosteffectivenessanalysis AT adedayoeojo estimatedhealthbenefitscostsandcosteffectivenessofeliminatingindustrialtransfattyacidsinnigeriacosteffectivenessanalysis AT clementinaeokoro estimatedhealthbenefitscostsandcosteffectivenessofeliminatingindustrialtransfattyacidsinnigeriacosteffectivenessanalysis AT abimbolaadegboye estimatedhealthbenefitscostsandcosteffectivenessofeliminatingindustrialtransfattyacidsinnigeriacosteffectivenessanalysis AT dikebojji estimatedhealthbenefitscostsandcosteffectivenessofeliminatingindustrialtransfattyacidsinnigeriacosteffectivenessanalysis |